- Business Wire•4 days ago
Simulations Plus, Inc. , a leading provider of modeling and simulation software for pharmaceutical discovery and development, today announced that it has been accepted into the SimInhale COST Action, a consortium composed of approximately 100 current university, research institute, and industry members from across Europe.
- Business Wire•18 days ago
Simulations Plus, Inc. , a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its fiscal fourth quarter and full fiscal year 2016 ended August 31, 2016.
- Business Wire•last month
Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released version 1.0 of PKPlus, its next-generation software for analysis of preclinical and clinical trial data.
Simulations Plus, Inc. (SLP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||8.77 x 100|
|Ask||8.86 x 100|
|Day's Range||8.77 - 9.18|
|52wk Range||6.74 - 11.89|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||32.61|
|Avg Vol (3m)||27,390|
|Dividend & Yield||0.20 (2.28%)|